Mayo Clinic Expands Partnership With Data Privacy Company TripleBlind

TripleBlind, the company that delivers automated, real-time data de-identification, has announced an expanded relationship with Mayo Clinic Platform. For the first time in healthcare, the use of TripleBlind’s Privacy Builder software will enable healthcare systems, via Mayo Clinic Platform, to strategically collaborate on developing the next generation of digital healthcare solutions within secure environments.

The collaboration allows Mayo Clinic Platform to:

• Analyze data without sharing it - TripleBlind facilitates this process through a patented combination of privacy-enhancing technologies. TripleBlind Privacy Builder is hardware and cloud agnostic, quantum-safe, and designed to securely foster data collaboration –– without seeing, sharing, or storing patient data.
  
  

• Develop algorithms and delivery insights - TripleBlind Privacy Builder enables Mayo Clinic Platform_Validate to test AI models without exposing any intellectual property.

“Mayo Clinic Platform’s vision is to create a healthier world where personalized, predictive and innovative care may be accessible to all,” said Steve Bethke, vice president of Mayo Clinic Platform product portfolio. “We’re excited to collaborate with TripleBlind to enable solution developers to validate their models, driving data-driven and scalable innovation in a secure environment.”

Mayo Clinic began investing in TripleBlind and using its application programming interface for digital health research in 2021.

In what seems to be a busy week for Mayo Clinic, it has also entered into a know-how and stock purchase agreement with Xsensio, a Swiss company for the development of new wearable products based on short-term health dynamics in critical care. 

Xsensio will work closely with Mayo Clinic subject matter experts who will provide clinical and product development expertise to Xsensio around the use of its proprietary health monitoring technology for critical care. The intent is to further accelerate innovation in the development of next-generation wearable solutions that provide continuous, real-time, on-body monitoring of biochemical data, with the goal of enhancing personalized early detection of rapidly evolving acute events, improving rapid clinical workflow, and enabling remote patient monitoring.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

Join the HealthXL Meeting on ‘Digital Biomarkers for Mental Health Evaluation and Management’ on 16th February. Click here to Request to Join. 

Click here to read the original news story.